{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:53:10Z","timestamp":1791409990109,"version":"4.3.3"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007186","name":"University of California Los Angeles Jonsson Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007186","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.clml.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T23:13:32Z","timestamp":1727824412000},"page":"162-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Social Determinants of Health on Peripheral T Cell Lymphoma Outcomes: Treatment Center-Type Emerges as a Powerful Prognostic Indicator"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9175-0189","authenticated-orcid":false,"given":"Monica","family":"Mead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4937-8181","authenticated-orcid":false,"given":"Beth","family":"Glenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angshuman","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.clml.2024.09.011_bib0001","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.09.011_bib0002","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","article-title":"Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification","volume":"15","author":"Savage","year":"2004","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.09.011_bib0003","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.09.011_bib0004","unstructured":"Available at: https:\/\/health.gov\/healthypeople\/objectives-and-data\/social-determinants-health, accessed: May 1, 2023."},{"key":"10.1016\/j.clml.2024.09.011_bib0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/bjh.13202","article-title":"Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era","volume":"168","author":"Petrich","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.clml.2024.09.011_bib0006","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral T-Cell lymphoma incidence and survival in the united states","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.09.011_bib0007","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3322\/caac.21314","article-title":"Cancer statistics for Hispanics\/Latinos, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.clml.2024.09.011_bib0008","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/bjh.15222","article-title":"Ethnic disparity in primary cutaneous CD30+T-cell lymphoproliferative disorders: an analysis of 1496 cases from the US national cancer database","volume":"181","author":"Su","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"15","key":"10.1016\/j.clml.2024.09.011_bib0009","doi-asserted-by":"crossref","first-page":"e18624","DOI":"10.1200\/JCO.2018.36.15_suppl.e18624","article-title":"Association of insurance status and race with overall survival among patients with cutaneous T-cell lymphoma: a national cancer database analysis","volume":"36","author":"Allen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.09.011_bib0010","doi-asserted-by":"crossref","first-page":"6466","DOI":"10.1182\/bloodadvances.2023010690","article-title":"Disparities in survival of hematologic malignancies in the context of social determinants of health: a systematic review","volume":"7","author":"Miranda-Galvis","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2024.09.011_bib0011","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/j.clml.2019.11.012","article-title":"Academic centers compared with nonacademic centers for patients with international prognostic index risk-stratified diffuse large B-cell lymphoma: a survival outcomes analysis","volume":"20","author":"Ermann","year":"2020","journal-title":"Clin Lymphoma Myeloma & Leuk"},{"issue":"18","key":"10.1016\/j.clml.2024.09.011_bib0012","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2217\/fon-2018-0596","article-title":"Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma","volume":"15","author":"Dhakal","year":"2019","journal-title":"Future Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.09.011_bib0013","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","article-title":"Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era","volume":"123","author":"Tao","year":"2014","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2024.09.011_bib0014","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1002\/cncr.30038","article-title":"Influence of the treatment facility volume on the survival of patients with non-Hodgkin lymphoma","volume":"122","author":"Go","year":"2016","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2024.09.011_bib0015","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1002\/cncr.29518","article-title":"Disparities in survival by insurance status in patients with Hodgkin lymphoma","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2024.09.011_bib0016","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2141.2011.08982.x","article-title":"Racial patterns of extranodal natural killer\/T-cell lymphoma, nasal type, in California: a population-based study","volume":"156","author":"Ai","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.clml.2024.09.011_bib0017","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1080\/10428194.2022.2102623","article-title":"Insurance-based disparities impact survival outcomes in Waldenstrom macroglobulinemia within the United States","volume":"63","author":"Chohan","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.09.011_bib0018","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/10428194.2020.1832669","article-title":"Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia","volume":"62","author":"Gunaratne","year":"2021","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.clml.2024.09.011_bib0019","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00277-023-05194-6","article-title":"Hospital facility characteristics and socioeconomic factors on outcomes and treatment in patients with multiple myeloma: national cancer database analysis","volume":"102","author":"Doucette","year":"2023","journal-title":"Ann. Hematol."},{"issue":"3","key":"10.1016\/j.clml.2024.09.011_bib0020","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.hemonc.2020.09.005","article-title":"Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma","volume":"14","author":"Jayakrishnan","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.09.011_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040590","article-title":"Socioeconomic factors and survival of multiple myeloma patients","volume":"13","author":"Chamoun","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.clml.2024.09.011_bib0022","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.clml.2019.01.004","article-title":"Overall survival trends and clinical characteristics of plasmacytoma in the united states: a national cancer database analysis","volume":"19","author":"Ghiassi-Nejad","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2024.09.011_bib0023","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2015.239","article-title":"Effect of the type of treatment facility on the outcome of acute myeloid leukemia in adolescents and young adults","volume":"30","author":"Go","year":"2016","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.clml.2024.09.011_bib0024","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1002\/cncr.30139","article-title":"Statewide geographic variation in outcomes for adults with acute myeloid leukemia in North Carolina","volume":"122","author":"Freeman","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2024.09.011_bib0025","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.21873\/anticanres.11057","article-title":"Insurance status and other non-biological factors predict outcomes in acute myelogenous leukemia: analysis of data from the national cancer database","volume":"36","author":"Master","year":"2016","journal-title":"Anticancer Res."},{"issue":"11","key":"10.1016\/j.clml.2024.09.011_bib0026","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1080\/10428194.2022.2090554","article-title":"Association of insurance types and outcomes in acute promyelocytic leukemia","volume":"63","author":"Dhakal","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.09.011_bib0027","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1080\/10428194.2021.1975187","article-title":"Acute lymphoblastic leukemia (ALL) in adults: disparities in treatment intervention based on access to treatment facility","volume":"63","author":"Khullar","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.09.011_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.19697","article-title":"Association of type of treatment facility with overall survival after a diagnosis of head and neck cancer","volume":"3","author":"Carey","year":"2020","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.clml.2024.09.011_bib0029","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2217\/fon-2021-0986","article-title":"Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer","volume":"18","author":"McAllister","year":"2022","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.09.011_bib0030","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1097\/MPA.0000000000001948","article-title":"Facility type affects treatment outcomes for patients with mucinous cystic neoplasms and intraductal papillary mucinous neoplasms of the pancreas","volume":"50","author":"Ahmad","year":"2021","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.clml.2024.09.011_bib0031","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.athoracsur.2020.05.051","article-title":"The academic facility type is associated with improved overall survival for early-stage lung cancer","volume":"111","author":"Merritt","year":"2021","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.clml.2024.09.011_bib0032","unstructured":"Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell.pdf, accessed: May 1, 2023."},{"key":"10.1016\/j.clml.2024.09.011_bib0033","unstructured":"Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/decentralized-clinical-trials-drugs-biological-products-and-devices, accessed: May 1, 2023"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024023565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:36:00Z","timestamp":1791408960000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024023565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2152265024023565"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Impact of Social Determinants of Health on Peripheral T Cell Lymphoma Outcomes: Treatment Center-Type Emerges as a Powerful Prognostic Indicator","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}